GlassScriptPhysician profile
Sugata Sensarma
NPI 1083604748
$7,388.19
in general payments reported to CMS, 2019-2025
37 companies · $1,262 in 2025
The $1,262 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $470 · 2021: $1,056 · 2022: $1,144 · 2023: $1,113 · 2024: $1,914 · 2025: $1,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,290.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,632.42 | 2020-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $947.76 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Actelion Pharmaceuticals US, INC. | $603.61 | 2020-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $520.81 | 2020-2025 | Stiolto Respimat, Spiriva Respimat, Jascayd |
| Insmed, INC. | $411.72 | 2021-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $407.15 | 2020-2025 | |
| Electromed, INC. | $253.19 | 2021-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $239.88 | 2020-2024 | Dupixent |
| United Therapeutics Corporation | $233.30 | 2021-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $226.83 | 2020-2025 | Prolastin-C Liquid |
| Baxter Healthcare | $205.75 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Amgen INC. | $180.82 | 2022-2025 | Tezspire |
| Mallinckrodt Hospital Products INC. | $180.33 | 2022-2025 | Acthar |
| Mylan Specialty L.P. | $157.38 | 2021-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $156.38 | 2019-2025 | Keytruda, Zerbaxa, Recarbrio |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sugata Sensarma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.